Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2025 · 10-Q
Revenue$45.33M$45.33M+46.3% vs Q1 2024 Net Income-$42.45M-$42.45MN/M vs Q1 2024 EPS Diluted-$2.21-$2.21N/M vs Q1 2024 Operating Income-$36,216,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived-$25,659,000N/M Margins · derivedOperating margin-79.9%−89.5 pt vs Q1 2024
Net margin-93.6%
ended Mar 31, 2025 · filed May 9, 2025 · 39 d after period end